Novartis
Itvisma
spinal muscular atrophy (SMA)
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for Itvisma in spinal muscular atrophy (SMA) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· Press release
verified 16h ago
“In STEER, Itvisma demonstrated a statistically significant 2.39-point improvement in the Hammersmith Functional Motor Scale (HFMSE) with effects sustained over 52 weeks of follow-up.”